{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:35:13Z","timestamp":1785771313079,"version":"3.56.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1097\/01.jcp.0000096253.95165.e8","type":"journal-article","created":{"date-parts":[[2003,11,18]],"date-time":"2003-11-18T07:31:58Z","timestamp":1069140718000},"page":"672-674","source":"Crossref","is-referenced-by-count":4,"title":["Atypical (Olanzapine) Plus Conventional (Fluphenazine) Neuroleptic Treatment Associated With the Neuroleptic Malignant Syndrome"],"prefix":"10.1097","volume":"23","author":[{"given":"Ian T.","family":"Tofler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0733-8627(05)70127-9","article-title":"The neuroleptic malignant and serotonin syndromes.","volume":"18","author":"Carbone","year":"2000","journal-title":"Emerg Med Clin North Am"},{"key":"R2-23-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7125(16)30278-4","article-title":"Neuroleptic malignant syndrome.","volume":"77","author":"Caroff","year":"1993","journal-title":"Med Clin North Am"},{"key":"R3-23-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/jnnp.69.2.277a","article-title":"Neuroleptic malignant syndrome without fever: a report of 3 cases.","volume":"69","author":"Peiras","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R4-23-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/jnp.6.1.1","article-title":"Malignant Catatonia.","volume":"6","author":"Philbrick","year":"1994","journal-title":"J Neuropsychiatry"},{"key":"R5-23-20210128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3928\/0048-5713-19960401-03","article-title":"What\u2019s happening to the Neuroleptic Malignant Syndrome?","volume":"26","author":"Simpson","year":"1996","journal-title":"Psychiatric Annals"},{"key":"R6-23-20210128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4088\/JCP.v63n0201","article-title":"Antipsychotic Polypharmacy. Squandering precious resources?","volume":"63","author":"Stahl","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R8-23-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","article-title":"Olanzapine, an updated review of its use in the management of schizophrenia.","volume":"61","author":"Bhana","year":"2001","journal-title":"Drugs"},{"key":"R9-23-20210128","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0893-133X(99)00129-3","article-title":"Allostasis and allostatic load. Implication for neuropsychopharmacology.","volume":"22","author":"McEwan","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"R10-23-20210128","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0033-3182(99)71247-8","article-title":"Neuroleptic malignant syndrome associated with olanzapine therapy.","volume":"40","author":"Apple","year":"1999","journal-title":"Psychosomatics"},{"key":"R11-23-20210128","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/jnnp.65.4.613","article-title":"\u201cNon neuroleptic-malignant\u201d syndrome.","volume":"65","author":"Larner","year":"1998","journal-title":"J Neurol N Surg Psychiatry"},{"key":"R12-23-20210128","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1176\/appi.psy.42.6.528","article-title":"Olanzapine useage associated with neuroleptic malignant syndrome.","volume":"42","author":"Philibert","year":"2001","journal-title":"Psychosomatics"},{"key":"R13-23-20210128","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptors explain the action of atypical antipsychotics? A new hypothesis.","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R14-23-20210128","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0006-3223(97)00530-1","article-title":"Clinical and pharmacologic risk factors for neuroleptic malignant syndrome. A case control study.","volume":"44","author":"Berardi","year":"1998","journal-title":"Biol Psychiatry"},{"key":"R16-23-20210128","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/appi.psy.43.6.505","article-title":"Letter re: Olanzapine and neuroleptic malignant syndrome.","volume":"43","author":"Tofler","year":"2002","journal-title":"Psychosomatics"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.jcp.0000096253.95165.e8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:42:39Z","timestamp":1785768159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200312000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jcp.0000096253.95165.e8","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}